Researchers measured bone area and bone mineral content by DXA in 164 Canadians repeatedly from childhood into their twenties and thirties. Bone area stopped growing one to two years before bone mineral content did, and peak bone mass was reached by the end of the second decade or early in the third, depending on the skeletal site. Close to 40% of adult total body bone mineral was gained in the four years around the growth spurt.
Peak bone mass is the most bone mineral a person ever has. It is reached in youth, and everything lost later comes off that starting point, which matters for fracture risk in old age. When it is reached was disputed: some studies put it around 20, others said bone was still being added into the thirties. Most earlier work was cross-sectional, and puberty starts up to five years apart in healthy children, so comparing people by birthday blurs the picture. The authors measured the same children repeatedly from age 8 into their twenties.
This is the Saskatchewan Pediatric Bone Mineral Accrual Study, an observational cohort with a mixed longitudinal design. From 1991, 220 students aged 8 to 15 at two Saskatoon schools had annual DXA scans, a low-dose X-ray that measures bone. Testing ran to 1997, paused five years, then resumed for up to four visits between 2002 and 2007. This analysis used only participants measured in both childhood and adulthood: 75 males and 89 females, 98% white and middle class. Bone area and mineral content were measured at the whole body, lumbar spine, total hip and femoral neck. Each person's data were aligned not on age but on their own age at peak height velocity, the point of fastest growth in height, averaging 11.8 years in girls and 13.5 in boys.
Bone area stopped growing first, and bone mineral content followed one to two years later.
In females, the mineral laid down across adolescence was double what is later lost between ages 50 and 80.
The cohort is 164 people, 98% white and middle class, from one Canadian city. The authors note that bone acquisition differs by ethnicity and that their results could be specific to this cohort and its environment. The upper age reached was about 30, so they cannot prove peak bone mass was final, only that it had plateaued. DXA carries measurement error and is affected by changing soft tissue, so average values do not land exactly at 100%. The authors also record a dispute in the field: some argue bone strength, not mass, determines fracture risk, and that no clear evidence yet links bone mass gained in youth to bone mass decades later. Funding came from Canadian public bodies, and all authors state they have no conflicts of interest.
The value here is timing. It shows the window for building bone closes earlier than often assumed, by the end of the second decade or very early in the third, and that much adult bone is laid down in the few years around the growth spurt. It tests no intervention. Nobody was given calcium, vitamin D or anything else, so it cannot say what raises peak bone mass. It is observational, in one narrow population. The authors compare their figures with a Chinese cohort whose girls accrued bone at similar rates on less than half the recommended calcium intake, a caution against reading nutrient intake into these numbers.
That depends on the specific medication and formula. A few, like blood thinners with CurQLife or blood pressure medication with MaxiNOs, are worth a direct conversation with your doctor first. Check each formula's own FAQ section for specifics, or ask your health coach.
No, and we'd rather be upfront about it. Bacopa, the plant in BacoZest, has published human studies, though they used other bacopa extracts. OptiNOs and MaxiNOs each have human studies sponsored by their maker, Laila Nutraceuticals, which haven't been published in a journal. CurQLife's research is still early, from lab and animal studies, and we label it that way.
It depends on what you're building your routine around. BacoZest is built around bacopa, which is studied for memory.* OptiNOs supports strength and muscular endurance alongside resistance training.* MaxiNOs was studied for healthy blood vessel function.* CurQLife's research is still at the lab stage. Your health coach can help you pick a starting point.
All four are built around plant extracts. OptiNOs was reported as well tolerated in its human study, and published bacopa studies reported no serious side effects. CurQLife's safety data so far comes from lab and animal testing. Check with your doctor first if you're pregnant, nursing, on medication, or managing a health condition.
Because the patented ingredients behind our four formulas went through dedicated research, and research costs real money. A generic curcumin or bacopa supplement hasn't been tested in the form you get from us. You're paying for an ingredient with research behind it, not just a label.
Generic ingredients often haven't been studied in the specific form you're buying. Our four core formulas use patented ingredients, and we show you the research behind each one, including where it's still early.
It depends on the formula. In its study, MaxiNOs blood vessel response was higher than placebo 2 to 3 hours after the first dose.* OptiNOs and bacopa were studied over 6 and 12 weeks of daily use, so give them time. CurQLife is meant to be taken daily.
Yes. BacoZest, OptiNOs, MaxiNOs, and CurQLife are built for different goals, and none of them contain stimulants. They haven't been studied together, so ask your health coach how to fit them into your routine.
